NCT04762875View on ClinicalTrials.gov

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

September 14, 2021

Study Completion Date

March 14, 2022

Conditions
Related Donors Donating PBSC to a Family MemberHealthy DonorsAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome
Interventions
BIOLOGICAL

MGTA-145

MGTA-145 will be be administered as an IV infusion

BIOLOGICAL

Plerixafor

240 µg/kg subcutaneously

Trial Locations (8)

14203

Roswell Park Cancer Institute, Buffalo

30322

Emory University Hospital, Atlanta

43210

Ohio State Medical Center, James Cancer Center, Columbus

55902

Mayo Clinic Rochester, Rochester

77030

M.D. Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

94305

Stanford Health Care, Stanford

98101

Be The Match Collection Center Seattle, Seattle

Sponsors

Lead Sponsor

Ensoma
All Listed Sponsors
collaborator

National Marrow Donor Program

OTHER

lead

Ensoma

INDUSTRY